301 related articles for article (PubMed ID: 19528873)
1. Autoradiographic studies of rhenium-188-hydroxyethylidine diphosphonate in normal skeleton and osteoblastic bone metastases in a rat model of metastatic prostate cancer.
Liepe K; Geidel HH; Bergmann R; Haase M; Runge R; Kotzerke J
Nucl Med Commun; 2009 Sep; 30(9):693-9. PubMed ID: 19528873
[TBL] [Abstract][Full Text] [Related]
2. Dosimetry of 188Re-hydroxyethylidene diphosphonate in human prostate cancer skeletal metastases.
Liepe K; Hliscs R; Kropp J; Runge R; Knapp FF; Franke WG
J Nucl Med; 2003 Jun; 44(6):953-60. PubMed ID: 12791825
[TBL] [Abstract][Full Text] [Related]
3. Radionuclide therapy for prostate cancer lumbar metastasis prolongs symptom-free survival in a rat model.
Geldof AA; van den Tillaar PL; Newling DW; Teule GJ
Urology; 1997 May; 49(5):795-801. PubMed ID: 9145995
[TBL] [Abstract][Full Text] [Related]
4. Bone marrow absorbed dose of rhenium-186-HEDP and the relationship with decreased platelet counts.
de Klerk JM; van Dieren EB; van het Schip AD; Hoekstra A; Zonnenberg BA; van Dijk A; Rutgers DH; Blijham GH; van Rijk PP
J Nucl Med; 1996 Jan; 37(1):38-41. PubMed ID: 8543998
[TBL] [Abstract][Full Text] [Related]
5. Rhenium-188(Sn)HEDP for treatment of osseous metastases.
Maxon HR; Schroder LE; Washburn LC; Thomas SR; Samaratunga RC; Biniakiewicz D; Moulton JS; Cummings D; Ehrhardt GJ; Morris V
J Nucl Med; 1998 Apr; 39(4):659-63. PubMed ID: 9544677
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of rhenium-186 after administration of rhenium-186-HEDP to patients with bone metastases.
de Klerk JM; van Dijk A; van het Schip AD; Zonnenberg BA; van Rijk PP
J Nucl Med; 1992 May; 33(5):646-51. PubMed ID: 1373767
[TBL] [Abstract][Full Text] [Related]
7. Treatment of metastatic bone pain using the bone seeking radiopharmaceutical Re-186-HEDP.
De Klerk JM; Zonnenberg BA; Blijham GH; Van Het Schip AD; Hoekstra A; Han SH; Quirijnen JM; Van Dijk A; Van Rijk PP
Anticancer Res; 1997; 17(3B):1773-7. PubMed ID: 9179233
[TBL] [Abstract][Full Text] [Related]
8. Transient cranial neuropathy in prostatic cancer with bone metastases after rhenium-186-HEDP treatment.
de Klerk JM; Zonnenberg BA; Krouwer HG; Blijham GH; van Dijk A; van het Schip AD; van Die J; van Rijk PP
J Nucl Med; 1996 Mar; 37(3):465-7. PubMed ID: 8772646
[TBL] [Abstract][Full Text] [Related]
9. Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: tandomized phase II trial with the new, high-energy radiopharmaceutical rhenium-188 hydroxyethylidenediphosphonate.
Palmedo H; Manka-Waluch A; Albers P; Schmidt-Wolf IG; Reinhardt M; Ezziddin S; Joe A; Roedel R; Fimmers R; Knapp FF; Guhlke S; Biersack HJ
J Clin Oncol; 2003 Aug; 21(15):2869-75. PubMed ID: 12885803
[TBL] [Abstract][Full Text] [Related]
10. A Monte Carlo simulation model for radiation dose to metastatic skeletal tumor from rhenium-186(Sn)-HEDP.
Samaratunga RC; Thomas SR; Hinnefeld JD; Von Kuster LC; Hyams DM; Moulton JS; Sperling MI; Maxon HR
J Nucl Med; 1995 Feb; 36(2):336-50. PubMed ID: 7830140
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of toxicity and efficacy of 186Re-hydroxyethylidene diphosphonate in patients with painful bone metastases of prostate or breast cancer.
Kolesnikov-Gauthier H; Carpentier P; Depreux P; Vennin P; Caty A; Sulman C
J Nucl Med; 2000 Oct; 41(10):1689-94. PubMed ID: 11037999
[TBL] [Abstract][Full Text] [Related]
12. Rhenium-186(Sn)HEDP for treatment of painful osseous metastases: results of a double-blind crossover comparison with placebo.
Maxon HR; Schroder LE; Hertzberg VS; Thomas SR; Englaro EE; Samaratunga R; Smith H; Moulton JS; Williams CC; Ehrhardt GJ
J Nucl Med; 1991 Oct; 32(10):1877-81. PubMed ID: 1717669
[TBL] [Abstract][Full Text] [Related]
13. A model-based method for the prediction of whole-body absorbed dose and bone marrow toxicity for 186Re-HEDP treatment of skeletal metastases from prostate cancer.
Buffa FM; Flux GD; Guy MJ; O'Sullivan JM; McCready VR; Chittenden SJ; Dearnaley DP
Eur J Nucl Med Mol Imaging; 2003 Aug; 30(8):1114-24. PubMed ID: 12761596
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic effects of a 186Re-complex-conjugated bisphosphonate for the palliation of metastatic bone pain in an animal model.
Ogawa K; Mukai T; Asano D; Kawashima H; Kinuya S; Shiba K; Hashimoto K; Mori H; Saji H
J Nucl Med; 2007 Jan; 48(1):122-7. PubMed ID: 17204708
[TBL] [Abstract][Full Text] [Related]
15. Bench to bedside development of GMP grade Rhenium-188-HEDP, a radiopharmaceutical for targeted treatment of painful bone metastases.
ter Heine R; Lange R; Breukels OB; Bloemendal HJ; Rummenie RG; Wakker AM; de Graaf H; Beekman FJ; van der Westerlaken MM; Malingré MM; Wielders JP; van den Berg L; Hendrikse NH; de Klerk JM
Int J Pharm; 2014 Apr; 465(1-2):317-24. PubMed ID: 24560635
[TBL] [Abstract][Full Text] [Related]
16. Significant antitumor effect from bone-seeking, alpha-particle-emitting (223)Ra demonstrated in an experimental skeletal metastases model.
Henriksen G; Breistøl K; Bruland ØS; Fodstad Ø; Larsen RH
Cancer Res; 2002 Jun; 62(11):3120-5. PubMed ID: 12036923
[TBL] [Abstract][Full Text] [Related]
17. Phase 1 study of rhenium-186-HEDP in patients with bone metastases originating from breast cancer.
de Klerk JM; van het Schip AD; Zonnenberg BA; van Dijk A; Quirijnen JM; Blijham GH; van Rijk PP
J Nucl Med; 1996 Feb; 37(2):244-9. PubMed ID: 8667053
[TBL] [Abstract][Full Text] [Related]
18. Radiation dose estimates of 186Re-hydroxyethylidene diphosphonate for palliation of metastatic osseous lesions: an animal model study.
van Aswegen A; Roodt A; Marais J; Botha JM; Naudé H; Lötter MG; Goedhals L; Doman MJ; Otto AC
Nucl Med Commun; 1997 Jun; 18(6):582-8. PubMed ID: 9259533
[TBL] [Abstract][Full Text] [Related]
19. Drug composition matters: the influence of carrier concentration on the radiochemical purity, hydroxyapatite affinity and in-vivo bone accumulation of the therapeutic radiopharmaceutical 188Rhenium-HEDP.
Lange R; de Klerk JMH; Bloemendal HJ; Ramakers RM; Beekman FJ; van der Westerlaken MML; Hendrikse NH; Ter Heine R
Nucl Med Biol; 2015 May; 42(5):465-469. PubMed ID: 25662844
[TBL] [Abstract][Full Text] [Related]
20. Dynamic studies with 99mTc-HEDP in normal subjects and in patients with bone tumors.
Citrin DL; Bessent RG; McGinley E; Gordon D
J Nucl Med; 1975 Oct; 16(10):886-90. PubMed ID: 809552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
